Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions
Sarcoma
Interventions
DRUG

Fluzoparib+ Dalpiciclib

"Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-3162~Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-6390"

Trial Locations (1)

510060

RECRUITING

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER